Sales for anti-angiogenic drugs.
作者信息
Ribatti Domenico
机构信息
Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, National Cancer Institute, Bari, Italy.
出版信息
Oncotarget. 2017 Jun 13;8(24):38080-38081. doi: 10.18632/oncotarget.17373.
Abstract
摘要
相似文献
1
Sales for anti-angiogenic drugs.抗血管生成药物的销售额。
Oncotarget. 2017 Jun 13;8(24):38080-38081. doi: 10.18632/oncotarget.17373.
2
Therapeutic application of anti-angiogenic nanomaterials in cancers.抗血管生成纳米材料在癌症治疗中的应用。
Nanoscale. 2016 Jul 7;8(25):12444-70. doi: 10.1039/c5nr07887c. Epub 2016 Apr 12.
3
Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.胃癌中的血管生成与抗血管生成治疗。
Int J Mol Sci. 2017 Dec 23;19(1):43. doi: 10.3390/ijms19010043.
4
Anti-angiogenic function of tocotrienol.生育三烯酚的抗血管生成功能。
Asia Pac J Clin Nutr. 2008;17 Suppl 1:253-6.
5
Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.血管生成因子作为潜在的药物靶点：抗血管生成治疗的疗效与局限性
Biochim Biophys Acta. 2014 Aug;1846(1):161-79. doi: 10.1016/j.bbcan.2014.05.002. Epub 2014 May 13.
6
Anti-angiogenic therapies in cancer: achievements and open questions.癌症中的抗血管生成疗法：成就与未决问题。
Bull Cancer. 2007 Sep;94(9):753-62.
7
A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.一种用于测定伊马替尼抗血管生成作用的绒毛尿囊膜模型。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):711-5. doi: 10.1016/j.ejpb.2013.07.010. Epub 2013 Jul 24.
8
Redundant angiogenic signaling and tumor drug resistance.冗余的血管生成信号与肿瘤耐药性
Drug Resist Updat. 2018 Jan;36:47-76. doi: 10.1016/j.drup.2018.01.002. Epub 2018 Jan 17.
9
[Anti-angiogenic drugs].
Nihon Rinsho. 2010 Oct;68(10):1825-9.
10
Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.天然化合物在癌症抗血管生成中的潜在作用。
Curr Vasc Pharmacol. 2017;15(6):503-519. doi: 10.2174/1570161115666170713094319.
引用本文的文献
1
Molecular Targeting of VEGF with a Suramin Fragment-DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins.通过模拟低分子量肝素的作用，用苏拉明片段-去氧皮质酮共轭物对血管内皮生长因子进行分子靶向
Biomolecules. 2020 Dec 31;11(1):46. doi: 10.3390/biom11010046.
本文引用的文献
1
Tumor refractoriness to anti-VEGF therapy.肿瘤对抗血管生成素治疗的难治性。
Oncotarget. 2016 Jul 19;7(29):46668-46677. doi: 10.18632/oncotarget.8694.
2
Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.卵巢癌患者的血管生成抑制剂：12项随机对照试验的荟萃分析。
Curr Med Res Opin. 2016;32(3):555-62. doi: 10.1185/03007995.2015.1131152. Epub 2016 Jan 13.
3
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.血管生成抑制剂在晚期非小细胞肺癌中的疗效与安全性：一项系统评价与荟萃分析
J Cancer Res Clin Oncol. 2015 May;141(5):909-21. doi: 10.1007/s00432-014-1862-5. Epub 2014 Nov 6.
4
From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti.从血管内皮生长因子的发现到阿瓦斯丁进入临床试验——多梅尼科·里巴蒂对拿破仑·费拉拉的采访
Int J Dev Biol. 2011;55(4-5):383-8. doi: 10.1387/ijdb.103216dr.
5
The inefficacy of antiangiogenic therapies.抗血管生成疗法的无效性。
J Angiogenes Res. 2010 Dec 10;2:27. doi: 10.1186/2040-2384-2-27.
6
Antiangiogenic therapy accelerates tumor metastasis.
Leuk Res. 2011 Jan;35(1):24-6. doi: 10.1016/j.leukres.2010.07.038. Epub 2010 Aug 19.
7
Biomarkers of response to angiogenesis inhibitors: an open and unsolved question.血管生成抑制剂反应的生物标志物：一个尚未解决的开放性问题。
Eur J Cancer. 2010 Jan;46(1):6-8. doi: 10.1016/j.ejca.2009.10.022.
8
Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance.为何治疗反应可能无法延长癌症患者的生命：致癌抗性的选择。
Cell Cycle. 2005 Dec;4(12):1693-8. doi: 10.4161/cc.4.12.2259. Epub 2005 Dec 15.
9
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.肿瘤血管正常化：抗血管生成治疗中的一个新兴概念。
Science. 2005 Jan 7;307(5706):58-62. doi: 10.1126/science.1104819.
10
Antiangiogenic therapy and tumor progression.抗血管生成疗法与肿瘤进展
Cancer Cell. 2004 Jan;5(1):13-7. doi: 10.1016/s1535-6108(03)00336-2.
Zotero 插件